{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:28:58Z","timestamp":1784658538040,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T00:00:00Z","timestamp":1464393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T00:00:00Z","timestamp":1464393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research Program on Hepatitis from Japan Agency for Medical Research and development, AMED."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00535-016-1225-x","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T08:50:28Z","timestamp":1464425428000},"page":"94-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1"],"prefix":"10.1007","volume":"52","author":[{"given":"Etsuko","family":"Iio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Kuramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Kusakabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokatsu","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,28]]},"reference":[{"issue":"Suppl 1","key":"1225_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","volume":"29","author":"D Lavanchy","year":"2009","unstructured":"Lavanchy D. The global burden of hepatitis C. Liver Int Off J Int Assoc Study Liver. 2009;29(Suppl 1):74\u201381.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"25","key":"1225_CR2","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. New Engl J Med. 2011;364(25):2405\u201316.","journal-title":"New Engl J Med"},{"issue":"12","key":"1225_CR3","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/jvh.12427","volume":"22","author":"E Ogawa","year":"2015","unstructured":"Ogawa E, Furusyo N, Dohmen K, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015;22(12):992\u20131001.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1225_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083\u201391.","journal-title":"Hepatology"},{"issue":"3","key":"1225_CR5","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902\u201311.","journal-title":"Hepatology"},{"issue":"9","key":"1225_CR6","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1225_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"JM Pawlotsky","year":"2013","unstructured":"Pawlotsky JM. NS5A inhibitors in the treatment of hepatitis C. J Hepatol. 2013;59(2):375\u201382.","journal-title":"J Hepatol"},{"issue":"5","key":"1225_CR8","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1128\/AAC.02494-12","volume":"57","author":"C Wang","year":"2013","unstructured":"Wang C, Sun JH, O\u2019Boyle DR 2nd, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57(5):2054\u201365.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1225_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3851\/IMP2729","volume":"19","author":"F McPhee","year":"2014","unstructured":"McPhee F, Hernandez D, Zhou N, et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir Ther. 2014;19(5):479\u201390.","journal-title":"Antivir Ther"},{"key":"1225_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02606-15","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Schnell G, Tripathi R, et al. Analysis of HCV genotype 1b resistance variants in Japanese patients treated with paritaprevir\/ritonavir and ombitasvir. Antimicrob Agents Chemother. 2015;. doi:10.1128\/AAC.02606-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1225_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","volume":"32","author":"F McPhee","year":"2015","unstructured":"McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther. 2015;32(7):637\u201349.","journal-title":"Adv Ther"},{"issue":"20","key":"1225_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. New Engl J Med. 2014;370(20):1879\u201388.","journal-title":"New Engl J Med"},{"issue":"1","key":"1225_CR13","first-page":"1","volume":"2","author":"T Kanda","year":"2014","unstructured":"Kanda T, Nakamoto S, Nakamura M, et al. Direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection. J Clin Transl Hepatol. 2014;2(1):1\u20136.","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"1225_CR14","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00535-015-1108-6","volume":"50","author":"Y Kai","year":"2015","unstructured":"Kai Y, Hikita H, Tatsumi T, et al. Emergence of hepatitis C virus NS5A L31\u00a0V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol. 2015;50(11):1145\u201351.","journal-title":"J Gastroenterol"},{"issue":"9","key":"1225_CR15","doi-asserted-by":"publisher","first-page":"e0138060","DOI":"10.1371\/journal.pone.0138060","volume":"10","author":"J Itakura","year":"2015","unstructured":"Itakura J, Kurosaki M, Higuchi M, et al. Resistance-associated NS5A variants of hepatitis C virus are susceptible to interferon-based therapy. PLoS One. 2015;10(9):e0138060.","journal-title":"PLoS One"},{"issue":"5","key":"1225_CR16","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.25826","volume":"56","author":"S Maekawa","year":"2012","unstructured":"Maekawa S, Sakamoto M, Miura M, et al. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology. 2012;56(5):1611\u201321.","journal-title":"Hepatology"},{"issue":"7","key":"1225_CR17","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.00308-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Friborg J, Levine S, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012;56(7):3670\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9941","key":"1225_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403\u201313.","journal-title":"Lancet"},{"issue":"5","key":"1225_CR19","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54(5):1878\u201387.","journal-title":"Antimicrob Agents Chemother"},{"key":"1225_CR20","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3009","author":"H Kan","year":"2015","unstructured":"Kan H, Hiraga N, Imamura M, et al. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice. Antivir Ther. 2015;. doi:10.3851\/IMP3009.","journal-title":"Antivir Ther"},{"issue":"4","key":"1225_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58(4):646\u201354.","journal-title":"J Hepatol"},{"key":"1225_CR22","doi-asserted-by":"crossref","unstructured":"Lenz O, de Bruijne J, Vijgen L, et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012;143(5):1176-8; e1-6.","DOI":"10.1053\/j.gastro.2012.07.117"},{"key":"1225_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24360","author":"N Akuta","year":"2015","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol. 2015;. doi:10.1002\/jmv.24360.","journal-title":"J Med Virol"},{"key":"1225_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13073","author":"H Kumada","year":"2015","unstructured":"Kumada H, Suzuki F, Suzuki Y, et al. Randomized comparison of daclatasvir\u00a0+\u00a0asunaprevir versus telaprevir\u00a0+\u00a0peginterferon\/ribavirin in Japanese HCV patients. J Gastroenterol Hepatol. 2015;. doi:10.1111\/jgh.13073.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"1225_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/hep.27559","volume":"61","author":"Y Fujii","year":"2015","unstructured":"Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology. 2015;61(1):400\u20131.","journal-title":"Hepatology"},{"issue":"5","key":"1225_CR26","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0016-5085(99)70402-6","volume":"117","author":"ML Shiffman","year":"1999","unstructured":"Shiffman ML, Hofmann CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology. 1999;117(5):1164\u201372.","journal-title":"Gastroenterology"},{"issue":"4","key":"1225_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29(4):1124\u201330.","journal-title":"Hepatology"},{"issue":"2","key":"1225_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.23691","volume":"52","author":"Y Asahina","year":"2010","unstructured":"Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2):518\u201327.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1225-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-016-1225-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1225-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-016-1225-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:52:40Z","timestamp":1659055960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-016-1225-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s00535-016-1225-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,28]]},"assertion":[{"value":"11 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yasuhito Tanaka is currently conducting research sponsored by Merck Sharp & Dohme, Corp., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and AbbVie Inc. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was (partially) supported by the Research Program on Hepatitis from Japan Agency for Medical Research and development, AMED.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}}]}}